Efficacy and safety of once-weekly semaglutide 2·4 mg in Chinese adults with overweight or obesity (STEP 12): a randomised, double-blind, placebo-controlled, multicentre, phase 3b trial

The Lancet Diabetes & Endocrinology · Elsevier

The publisher did not provide an abstract — full text is available via the link below.

Read at publisher →

Similar articles